|
Schizophrenia
|
0.300 |
Biomarker
|
disease |
PSYGENET |
In addition, Western blots showed that antibody against ERV9 pol protein in serum from the HERV+ schizophrenia patients, but not from control (p<0.01).
|
16531011 |
2006 |
|
Schizoaffective Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
We found sequences homologous to retroviral pol genes in the cell-free cerebrospinal fluids (CSFs) of 10 of 35 (29%) individuals with recent-onset schizophrenia or schizoaffective disorder.
|
11296294 |
2001 |
|
Schizophrenia
|
0.300 |
Biomarker
|
disease |
PSYGENET |
We found sequences homologous to retroviral pol genes in the cell-free cerebrospinal fluids (CSFs) of 10 of 35 (29%) individuals with recent-onset schizophrenia or schizoaffective disorder.
|
11296294 |
2001 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Portuguese HIV-1 subtype B and G pol genetic sequences were appended to global reference data sets to identify country-specific transmission clades.
|
30805610 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
Biomarker
|
disease |
BEFREE |
The gp120 envelope protein, Nef protein and Pol protein are particularly similar to host TCR, camouflaging HIV from the immune system and creating serious barriers to the development of safe HIV vaccines.
|
28972547 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Programmed '-1' ribosomal frameshifting is necessary for expressing the pol gene overlapped from a gag of human immunodeficiency virus.
|
27485859 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
Biomarker
|
disease |
BEFREE |
Moreover, we have used pre-steady-state kinetics to examine the incorporation of 8-oxo-dGTP opposite m<sup>6</sup>A relative to A by a variety of reverse transcriptase (RT) enzymes and DNA polymerase (DNA pol) enzymes such as the human immunodeficiency virus type 1 (HIV-1) RT and human DNA pol β.
|
29308175 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Drug resistance mutations in the Pol gene of human immunodeficiency virus 1 (HIV-1) are one of the critical factors associated with antiretroviral therapy (ART) failure in HIV-1 patients.
|
26801790 |
2016 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The human immunodeficiency virus type 1 p6 region encodes p6(Gag) and the transframe p6(Pol) protein.
|
15039534 |
2004 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.
|
7983713 |
1995 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Comparison of the Pol protein, usually highly conserved within the HIV-1 family, shows only about 73% similarity with the HIVmm isolate, whereas for the more variable proteins such as envelope, similarities of 50% or lower are found.
|
8107220 |
1994 |
|
Hepatitis B
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Thus, during treatment, mutations in the POL gene may lead to changes in hepatitis B surface antigen (HBsAg).
|
24165277 |
2013 |
|
Hepatitis B
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The Abbott HBV RUO Sequencing assay (Abbott Molecular Inc., Des Plaines, IL), which combines automated sample processing, real-time PCR, and bidirectional DNA sequencing, was evaluated for detection of nucleos(t)ide analogue (NA) resistance-associated mutations located in the hepatitis B virus (HBV) polymerase (Pol) gene.
|
23100352 |
2013 |
|
Hepatitis B
|
0.060 |
Biomarker
|
disease |
BEFREE |
To prime multispecific T cell responses, we constructed DNA vaccines that coexpress chimeric, multidomain Ags (with CD8 T cell-defined epitopes of the hepatitis B virus (HBV) surface (S), core (C), and polymerase (Pol) proteins and/or the OVA Ag as stress protein-capturing fusion proteins.
|
19542448 |
2009 |
|
Hepatitis B
|
0.060 |
Biomarker
|
disease |
BEFREE |
The HBV polymerase (Pol) gene overlaps the hepatitis B surface antigen (HBsAg) in a frame-shifted manner with the result that drug-resistant mutations in the HBV Pol can directly impact on the nature of HBsAg and its function.
|
16622878 |
2006 |
|
Hepatitis B
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
This correlated with reduced levels of secreted hepatitis B e antigen and increased intracellular levels of core and Pol proteins and replicative HBV DNA intermediates.
|
8970951 |
1996 |
|
Hepatitis B
|
0.060 |
Biomarker
|
disease |
BEFREE |
Putative reverse transcriptase intermediates of human hepatitis B virus in primary liver carcinomas.
|
2418501 |
1986 |
|
Fibromuscular Dysplasia
|
0.030 |
Biomarker
|
disease |
BEFREE |
High incidence and clinical characteristics of fibromuscular dysplasia in patients with spontaneous cervical artery dissection: The ARCADIA-POL study.
|
30739593 |
2019 |
|
Fibromuscular Dysplasia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Prevalence of smoking and clinical characteristics in fibromuscular dysplasia. The ARCADIA-POL study.
|
30560699 |
2019 |
|
Fibromuscular Dysplasia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Echocardiographic assessment of left ventricular morphology and function in patients with fibromuscular dysplasia: the ARCADIA-POL study.
|
29528871 |
2018 |
|
Fanconi Anemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
SMI#9 attenuated cisplatin-induced PCNA monoubiquitination (TLS marker), FANCD2 (Fanconi anemia (FA) activation marker), and TLS polymerase POL η. SMI#9-induced decreases in γH2AX levels were associated with concomitant inhibition of H2AX monoubiquitination, suggesting a key role for RAD6 in modulating cisplatin-induced γH2AX via H2AX monoubiquitination.
|
31639439 |
2020 |
|
FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
SMI#9 attenuated cisplatin-induced PCNA monoubiquitination (TLS marker), FANCD2 (Fanconi anemia (FA) activation marker), and TLS polymerase POL η. SMI#9-induced decreases in γH2AX levels were associated with concomitant inhibition of H2AX monoubiquitination, suggesting a key role for RAD6 in modulating cisplatin-induced γH2AX via H2AX monoubiquitination.
|
31639439 |
2020 |
|
Varicella zoster
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Altogether, this study provides significant extension on the current knowledge on susceptibility to VZV infection by demonstrating mutations in POL III genes associated with impaired immunological sensing of AT-rich DNA in adult patients with VZV CNS infection.
|
29728610 |
2019 |
|
Varicella zoster
|
0.020 |
Biomarker
|
disease |
BEFREE |
We present the latest knowledge on the role of POL III in VZV infection and discuss outstanding questions related to the role of POL III in VZV immunity, and how this insight can be translated into clinical medicine.
|
30115567 |
2018 |
|
Fanconi Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The compromised DNA repair and chemosensitization induced by SMI#9 or <i>RAD6B</i> depletion were associated with decreased platinum drug-induced proliferating cell nuclear antigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, respectively) and with attenuated FANCD2, RAD6, γH2AX, and POL η foci formation and cisplatin-adduct removal.
|
28490629 |
2017 |